地塞米松对心脏手术后早期认知功能下降的影响:一项随机对照试验
该单中心随机对照试验纳入169例择期心脏手术患者,术前10小时单次静脉给予地塞米松0.1 mg/kg或安慰剂,主要终点为术后第6天POCD发生率。结果显示地塞米松组POCD发生率显著降低(RR 0.43,95%CI 0.21-0.89,P=0.02),并降低全身炎症反应综合征发生率和术后C反应蛋白水平,但S100β蛋白水平无显著差异。
要点
- 术前10小时单次静脉地塞米松0.1 mg/kg可降低心脏手术后第6天POCD发生率。
- 地塞米松组全身炎症反应综合征发生率和术后C反应蛋白水平显著低于安慰剂组。
- 术后S100β蛋白水平两组间无显著差异。
核心结论
- 术前给予地塞米松可减轻炎症反应,从而降低心脏手术后早期POCD风险。
研究设计与样本
- 随机对照研究,单中心大学教学医院,2015年3月至2016年1月,169例择期心脏手术患者入组,161例纳入分析。
主要发现
- 地塞米松组POCD发生率较安慰剂组显著降低(RR 0.43,95%CI 0.21-0.89,P=0.02)。
- 地塞米松组全身炎症反应综合征发生率显著低于安慰剂组(30.0% vs 58.0%,P<0.001)。
- 地塞米松组术后C反应蛋白水平显著低于安慰剂组(P<0.001)。
- 术后S100β蛋白水平地塞米松组较低但无统计学意义(P=0.56)。
关键数值与推荐
- 地塞米松用法:术前10小时单次静脉推注0.1 mg/kg。
- 主要终点:术后第6天POCD发生率。
- 次要终点:全身炎症反应综合征发生率、术后C反应蛋白水平、术后血清S100β蛋白水平。
临床怎么用
- 对择期心脏手术患者,可考虑术前10小时单次静脉给予地塞米松0.1 mg/kg以降低早期POCD风险,但需结合患者个体情况权衡利弊。
局限性
- 单中心研究,样本量有限(161例纳入分析),结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Postoperative cognitive decline (POCD), a very common complication after cardiac surgery, is characterised by impairment of both memory function and intellectual ability as well as being associated with increased use of healthcare resources. The investigators focused on the role of the inflammatory response to a surgical procedure as a potential factor involved in the pathogenesis of POCD. OBJECTIVE: The use of prophylactic dexamethasone to attenuate the inflammatory response was hypothesised to reduce the risk of POCD. DESIGN: Randomised controlled study. SETTING: Single university teaching hospital, from March 2015 to January 2016. PATIENTS: A total of 169 patients scheduled for elective cardiac surgery were enrolled, and 161 patients were included in the analyses. INTERVENTION: Patients were randomised to receive a single intravenous bolus of 0.1 mg kg dexamethasone (n = 85) or placebo (n = 84) 10 h before the surgery. MAIN OUTCOME MEASURES: The primary outcome measure in both groups was the incidence of POCD on the 6th day after surgery. The investigators also evaluated the effect of dexamethasone on the incidence of systemic inflammatory response syndrome, postoperative C-reactive protein levels and postoperative serum S100β protein levels. RESULTS: Compared to the placebo group, the dexamethasone group showed statistically significant reductions in the incidence of POCD (relative risk, 0.43; 95% confidence interval, 0.21 to 0.89; P = 0.02), the incidence of systemic inflammatory response syndrome (30.0 versus 58.0%, P < 0.001) and postoperative C-reactive protein levels (P < 0.001). Postoperative S100β levels were insignificantly lower (P = 0.56) in the dexamethasone group. CONCLUSION: Preoperative administration of dexamethasone reduced the inflammatory response and thereby decreased the risk of early POCD after cardiac surgery. TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT02767713.
引用
- Glumac S, Kardum G, Sodic L, et al. Effects of dexamethasone on early cognitive decline after cardiac surgery: A randomised controlled trial. Eur J Anaesthesiol. 2017. PMID: 28985195. doi:10.1097/EJA.0000000000000647
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。